Gossamer Bio announces up to $250 million private placement
Gossamer Bio says it has entered a structured private placement for up to $250 million, including $150 million of committed capital, to fund seralutinib through potential FDA approval.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.